SCHEMBL4959801

SCHEMBL4959801

O=C(ONNCC1CCCCC1)C(F)(F)F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 6/20 0.43
HDAC3 O15379 4/20 0.43
HDAC4 P56524 3/20 0.43
HDAC1 Q13547 3/20 0.43
MLYCD O95822 1/20 0.42
EPHX1 P07099 4/20 0.40
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
MMP1 P03956 1/20 0.38
MMP2 P08253 1/20 0.38
MMP3 P08254 1/20 0.38
MMP9 P14780 1/20 0.38
MMP8 P22894 1/20 0.38
CA9 Q16790 1/20 0.38
CYP2D6 P10635 1/20 0.37
KDM4E B2RXH2 2/20 0.36
POLB P06746 2/20 0.36
ALDH1A1 P00352 1/20 0.36
ADH1B P00325 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5091808 0.95 HDAC6 (0.38) HDAC6HDAC3HDAC4HDAC1MLYCD
SCHEMBL3488617 0.84 CNR2 (0.32) HDAC6HDAC3HDAC4HDAC1CYP2D6
SCHEMBL4432362 0.75 HDAC3 (0.40) HDAC6HDAC3HDAC4HDAC1MLYCD
SCHEMBL4114063 0.72 PDK1 (0.36) EPHX1KDM4EALDH1A1
SCHEMBL3379859 0.69 HDAC6 (0.55) HDAC6HDAC3HDAC4HDAC1MLYCD
SCHEMBL27746258 0.69 EPHX1 (0.41) EPHX1CA12CA1CA2MMP2
SCHEMBL1787822 0.69 EPHX1 (0.41) EPHX1CA12CA1CA2MMP2
SCHEMBL10150825 0.69 LMNA (0.50) HDAC6MLYCDEPHX1HPGD
SCHEMBL8512564 0.69 CA2 (0.36) CA2POLBALDH1A1
SCHEMBL27718892 0.68 HDAC3 (0.41) HDAC6HDAC3HDAC4HDAC1MLYCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1542972-A4 CYCLOOXYGENASE- 2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE NITROMED INC (US) 2008-01-23 EP disclosed
US-20070238735-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use NITRODMED, INC. (US) 2007-10-11 US disclosed
US-7244753-B2 Cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2007-07-17 US disclosed
EP-1542972-A2 CYCLOOXYGENASE- 2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE Nitromed, Inc. (US) 2005-06-22 EP disclosed
US-20040072883-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. 2004-04-15 US disclosed
WO-2004010945-A2 CYCLOOXYGENASE- 2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2004-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072883-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use PTGS2, PTGIS, PTGES2 HDAC6 2960/4885HDAC3 3852/4885HDAC4 3902/4885
US-20070238735-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use PTGS2, PTGIS, PTGS1 HDAC6 3323/4885HDAC3 3736/4885HDAC4 4129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.